We validated our genetic knockdown results using pharmacologic agents, via selective SSTR3 antagonism which as a therapeutic approach has shown promise as a treatment for type 2 diabetes by boosting insulin secretion in preclinical models and in human islets ex vivo. Here, INS is linked to type 2 diabetes mellitus.